Compare BHR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | IMUX |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 100.2M |
| IPO Year | 2013 | 2013 |
| Metric | BHR | IMUX |
|---|---|---|
| Price | $1.66 | $8.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $2.00 | ★ $43.09 |
| AVG Volume (30 Days) | ★ 655.2K | 272.8K |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $487,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.18 | $0.51 |
| 52 Week High | $3.19 | $17.43 |
| Indicator | BHR | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 51.03 |
| Support Level | $1.30 | $0.87 |
| Resistance Level | $2.61 | $8.41 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.05 | 0.22 |
| Stochastic Oscillator | 92.31 | 81.05 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.